Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ocular toxoplasmosis during natalizumab treatment.

× No keyword cloud information.

15 in total

1. Hydrocephalus during natalizumab treatment.

Authors: Chiara Zecca; Claudio Städler; Claudio Gobbi
Journal: Neurol Sci Date: 2010-05-08 Impact factor: 3.307

2. CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors: Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal: Invest Ophthalmol Vis Sci Date: 2011-01-21 Impact factor: 4.799

3. VCAM-1/α4β1 integrin interaction is crucial for prompt recruitment of immune T cells into the brain during the early stage of reactivation of chronic infection with Toxoplasma gondii to prevent toxoplasmic encephalitis.

Authors: Qila Sa; Eri Ochiai; Tomoko Sengoku; Melinda E Wilson; Morgan Brogli; Stephen Crutcher; Sara A Michie; Baohui Xu; Laura Payne; Xisheng Wang; Yasuhiro Suzuki
Journal: Infect Immun Date: 2014-04-21 Impact factor: 3.441

Ocular toxoplasmosis during natalizumab treatment.

1. Hydrocephalus during natalizumab treatment.

2. CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

3. VCAM-1/α4β1 integrin interaction is crucial for prompt recruitment of immune T cells into the brain during the early stage of reactivation of chronic infection with Toxoplasma gondii to prevent toxoplasmic encephalitis.

Review 4. The occurrence and prevention of foodborne disease in vulnerable people.

Review 5. Disease-modifying therapies and infectious risks in multiple sclerosis.

6. [Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

Review 7. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Review 8. Infectious Complications of Novel Multiple Sclerosis Therapies.

Review 9. Natalizumab therapy for multiple sclerosis.

10. Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.